Therapeutic Plasma Exchange in AChR-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response

References

• Liu F, Wang Q, Chen X. Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. BMC Neurol. 2019;19(1):172. doi:10.1186/s12883-019-1384-5
   PubMedGoogle Scholar
• Lv Z, Zhong H, Huan X, et al. Predictive score for in-hospital mortality of myasthenic crisis: a retrospective Chinese cohort study. Eur Neurol. 2019;81(5–6):287–293. doi:10.1159/000503961
   PubMed Web of Science ®Google Scholar
• Hsu CW, Chen NC, Huang WC, et al. Hemogram parameters can predict in-hospital mortality of patients with Myasthenic crisis. BMC Neurol. 2021;21(1):388. doi:10.1186/s12883-021-02412-4
   PubMed Web of Science ®Google Scholar
• Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122. doi:10.1212/WNL.0000000000011124
   PubMed Web of Science ®Google Scholar
• Morren J, Li Y. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review. Muscle Nerve. 2018;58(3):344–358. doi:10.1002/mus.26107
   PubMed Web of Science ®Google Scholar
• Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):129–138. doi:10.1016/j.ejogrb.2005.01.002
   PubMed Web of Science ®Google Scholar
• Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575–580. doi:10.1001/jamaneurol.2014.17
   PubMed Web of Science ®Google Scholar
• Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: a Systematic Literature Review and Meta-Analysis of Comparative Evidence. Front Neurol. 2021;12:662856. doi:10.3389/fneur.2021.662856
   PubMed Web of Science ®Google Scholar
• Morales-Ruiz V, Juárez-Vaquera VH, Rosetti-Sciutto M, Sánchez-Muñoz F, Adalid-Peralta L. Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis. Autoimmun Rev. 2022;21(3):103019. doi:10.1016/j.autrev.2021.103019
   PubMed Web of Science ®Google Scholar
• Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063. doi:10.1016/j.lanwpc.2020.100063
   PubMedGoogle Scholar
• Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmüller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715–728. doi:10.1007/s40273-020-00912-8
   PubMed Web of Science ®Google Scholar
• Neuroimmunology of Chinese Immunology Society. Chinese guidelines for diagnosis and treatment of myasthenia gravis 2020. Chin J Neuroimmunol Neurol. 2021;28(1):1–12. doi:10.3969/j.issn.1006-2963.2021.01.001
   Google Scholar
• Chen J, Li S, Feng L, Wang H, Huang X, Feng H. Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis. Neurol Sci. 2023;44(3):1049–1057. doi:10.1007/s10072-022-06493-y
   PubMed Web of Science ®Google Scholar
• Wang Y, Huan X, Jiao K, et al. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol. 2022;241:109058. doi:10.1016/j.clim.2022.109058
   PubMed Web of Science ®Google Scholar
• Dhawan PS, Goodman BP, Harper CM, et al. IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic. Neurologist. 2015;19(5):145–148. doi:10.1097/NRL.0000000000000026
   PubMed Web of Science ®Google Scholar
• Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the United States. J Clin Neuromuscul Dis. 2020;22(1):11–21. doi:10.1097/CND.0000000000000301
   PubMedGoogle Scholar
• Chen J, Shang W, Chen Y, et al. Thymomatous myasthenia gravis: 10-year experience of a single center. Acta Neurol Scand. 2021;143(1):96–102. doi:10.1111/ane.13332
   PubMed Web of Science ®Google Scholar
• Dogra A, Rana K, Rathod C, Prakash S. Outcome of therapeutic plasma exchange in myasthenia gravis patients. J Family Med Prim Care. 2020;9(12):5971–5975. doi:10.4103/jfmpc.jfmpc_1026_20
   PubMedGoogle Scholar
• Rath J, Brunner I, Tomschik M, et al. Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol. 2020;267(4):1004–1011. doi:10.1007/s00415-019-09667-55
   PubMed Web of Science ®Google Scholar
• Rønager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967–973. doi:10.1046/j.1525-1594.2001.06717.x
   PubMed Web of Science ®Google Scholar
• Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472–479. doi:10.1080/08916934.2016.1214823
   PubMed Web of Science ®Google Scholar
• Ching J, Richards D, Lewis RA, Li Y. Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis. Muscle Nerve. 2021;64(4):483–487. doi:10.1002/mus.27341
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354. doi:10.1002/jca.21705
   PubMed Web of Science ®Google Scholar
• Sheckley H, Malhotra K, Katyal N, Narula N, Govindarajan R. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis. J Clin Apher. 2021;36(5):727–736. doi:10.1002/jca.21923
   PubMed Web of Science ®Google Scholar
• Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415–432. doi:10.1038/s41577-022-00821-1
   PubMed Web of Science ®Google Scholar
• Di Stefano V, Alonge P, Rini N, et al. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol. 2024;271(1):254–262. doi:10.1007/s00415-023-11970-1
   PubMedGoogle Scholar
• Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol. 2021;20(7):526–536. doi:10.1016/S1474-4422(21)00159-9
   PubMed Web of Science ®Google Scholar
• Maho-Vaillant M, Sips M, Golinski ML, et al. FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Front Immunol. 2022;13:863095. doi:10.3389/fimmu.2022.863095
   PubMed Web of Science ®Google Scholar
• Mina-Osorio P, Tran MH, Habib AA. Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease. Transfus Med Rev. 2024;38(1):150767. doi:10.1016/j.tmrv.2023.150767
   PubMed Web of Science ®Google Scholar
• Soltész P, Aleksza M, Antal-Szalmás P, Lakos G, Szegedi G, Kiss E. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity. 2002;35(1):51–56. doi:10.1080/08916930290005909
   PubMed Web of Science ®Google Scholar
• Glassman AB, Bennett CE. Alterations of lymphocyte responsiveness in Guillain-Barré syndrome. effects of plasma exchange. Transfusion. 1983;23(5):369–372. doi:10.1046/j.1537-2995.1983.23584018711.x
   PubMed Web of Science ®Google Scholar
• Bennani HN, Lagrange E, Noble J, et al. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: a case series of nine patients and literature review. J Clin Apher. 2021;36(3):348–363. doi:10.1002/jca.21868
   PubMed Web of Science ®Google Scholar